Drug Profile
Doxorubicin drug delivery system - Delcath Systems
Latest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Delcath Systems
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 29 Mar 2015 No recent reports of development identified - Registered for Liver cancer in Europe (Intrahepatic)
- 26 Nov 2012 Doxorubicin drug delivery system - Delcath Systems is available for licensing in Asia as of 22 Oct 2012. www.Delcath.com
- 22 Oct 2012 Registered for Liver cancer in Europe (Intrahepatic)